Clinical outcomes of a remimazolam-based sedation regimen in patients receiving ECMO: a retrospective comparative study
-
By
-
Dalong Zhang
-
Ying Liu
-
Tongrui Zhang
-
Yuanjie Shang
-
Huijun Dong
-
Xingguo Niu
-
June 8, 2026
-
Clinical Scorecard: Outcomes of Sedation Using Remimazolam Compared to Midazolam in ECMO Patients: A Retrospective Analysis
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | |
| Care Setting | |
Key Highlights
- Delirium incidence: 0% in remimazolam group vs. 27.3% in midazolam group (p = 0.021)
- Shorter recovery time after decannulation with remimazolam (24.90 h vs. 29.84 h, p < 0.001)
- Better-preserved muscle strength in remimazolam group (median MRC grade 1 vs. 0, p < 0.001)
- Lower incidences of hypotension and bradycardia in remimazolam group (both p < 0.05)
- Study suggests remimazolam may reduce delirium risk in ECMO patients
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Adults receiving veno-arterial ECMO support
Remimazolam associated with lower delirium and faster recovery compared to midazolam
Clinical Best Practices
Related Resources & Content
